Oncology

Mallinckrodt has announced to sell its Canadian drug manufacturing BioVectra Inc. to a Miami-based private equity firm, an affiliate of H.I.G. Capital for approximately USD 250 Million. The agreement included a fixed amount of USD 175 Million, with an upfront amount of USD 135 Million, a long term payment of USD 135 Million and further liable payments of USD 75 Million.  The agreement will let Mallinckrodt, a global pharmaceutical company advancing the development and manufacturing of speciality generic drug, to have the full ownership of BioVectra and seize its future potential. BioVectra, a contract development and manufacturing organization (CDMO), ser...